Researchers at the University of Pittsburgh have identified a trigger of high-grade serous ovarian cancer: a subset of progenitor cells that reside in fallopian tube supportive tissue, or stroma.
Scientists at VCU Massey Comprehensive Cancer Center found that combination therapy of sotorasib (Lumakras)—an FDA-approved drug in the market—and an experimental drug called FGTI-2734, could make precision medicine more effective for patients with a highly resistant form of lung cancer.
UT Southwestern Medical Center researchers developed a “self-driving” microscope that solves two challenges that have long plagued microscopy: 1) imaging living cells or organisms at dramatically different scales, and 2) following a specific structure or area of interest over long periods of time.
In findings published in Clinical Cancer Research, a research team at Mayo Clinic identified specific proteins—fibronectin and smooth muscle actin—within colorectal cancer tissues that are associated with resistance to immunotherapy treatment.
The American Society for Radiation Oncology issued a clinical guideline on the use of radiation therapy to treat adult patients with primary squamous cell carcinoma of the anal canal and anal margin.
B-cell acute lymphoblastic leukemia is a common type of ALL in adults.
A five-year study on subjects who had only the cancerous portion of their prostate glands destroyed shows that the procedure averted cancer recurrence in most patients while preserving urinary and sexual function.
A study by University of Arizona Health Sciences researchers found that an immunotherapy previously shown to be ineffective against prostate cancer may have therapeutic potential when combined with a synergistic treatment approach.
The phase III VERIFY trial, in which phlebotomy-dependent patients with polycythemia vera were randomized to treatment with either rusfertide (PTG-300) or placebo, as an add-on to standard of care treatment, met its primary endpoint of proportion of patients achieving response.
A new analysis by the International Agency for Research on Cancer and collaborators evaluates the latest and future global burden of female breast cancer in about 50 countries worldwide.
